Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study and Open-Label Extension of SC411 in Children With Sickle Cell Disease

Next Previous
X
Search
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study and Open-Label Extension of SC411 in Children With Sickle Cell Disease

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docosahexaenoic acid (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SCOT
  • Sponsors Sancilio & Company

    • Most Recent Events

    • 29 Jan 2019 Planned End Date changed from 30 Jul 2019 to 2 Jan 2022.
    • 30 Apr 2018 According to a Sancilio & Company media release, Sixty-two subjects (93%) completed the blinded portion of the study, with 41 opting to participate in the Open Label Extension (OLE) study.
    • 30 Apr 2018 Results presented in a Sancilio & Company media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top